2009 H1N1 influenza

Mayo Clinic Proceedings

Volumn 85, Issue 1, 2010, Pages 64-76

  Sullivan, Seth J ^a   Jacobson, Robert M ^a   Dowdle, Walter R ^b   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b The Task Force for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE; ZANAMIVIR;

ANGIONEUROTIC EDEMA; ANTIGENIC VARIATION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTHRALGIA; AUTOMUTILATION; CHEMOPROPHYLAXIS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; CROSS REACTION; DELIRIUM; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FEVER; GROUP A STREPTOCOCCAL INFECTION; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFECTION; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOGENICITY; INCUBATION TIME; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; INJECTION SITE SWELLING; LUNG LAVAGE; MEDICAL INFORMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; MORTALITY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; NOSE CONGESTION; PATIENT COUNSELING; PNEUMOCOCCAL INFECTION; PREGNANCY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATION DEPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHINORRHEA; SINGLE DRUG DOSE; SORE THROAT; STOMACH PAIN; STREPTOCOCCUS INFECTION; THORAX RADIOGRAPHY; THROAT CULTURE; TRACHEAL ASPIRATION PROCEDURE; TREATMENT RESPONSE; VACCINATION; VIRUS ATTACHMENT; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS TRANSMISSION; VOMITING;

EID: 73649085852     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0588     Document Type: Review

References (104)

1. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children - Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(15):400-402.
2. Centers for Disease Control and Prevention (CDC). Update: swine influenza A (H1N1) infections - California and Texas, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(16):435-437.
3. Centers for Disease Control and Prevention (CDC). Update: novel influenza A (H1N1) virus infection - Mexico, March-May, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(21):585-589.
4. World Health Organization. Current WHO phase of pandemic alert. World Health Organization website. http://www.who.int/csr/disease/avian-influenza/ phase/en/index.html. Accessed November 10, 2009.
5. Zimmer SM, Burke DS. Historical perspective - emergence of influenza A (H1N1) viruses. N Engl J Med. 2009;361(3):279-285.
6. Shope RE. The incidence of neutralizing antibodies for swine influenza virus in the sera of human beings of different ages. J Exp Med. 1936;63(5):669-684.
7. Nakajima K, Nobusawa E, Nakajima S. Genetic relatedness between A/Swine/Iowa/15/30(H1N1) and human influenza viruses. Virology. 1984;139(1):194-198.
8. Gorman OT, Bean WJ, Kawaoka Y, Donatelli I, Guo YJ, Webster RG. Evolution of influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and classical swine viruses. J Virol. 1991;65(7):3704-3714.
9. Kanegae Y, Sugita S, Shortridge KF, Yoshioka Y, Nerome K. Origin and evolutionary pathways of the H1 hemagglutinin gene of avian, swine and human influenza viruses: cocirculation of two distinct lineages of swine virus. Arch Virol. 1994;134(1-2):17-28.
10. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology. 1978;87(1):13-20.
11. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9-14.
12. Gaydos JC, Top FH Jr, Hodder RA, Russell PK. Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis. 2006;12(1):23-28.
13. Scholtissek C, von Hoyningen V, Rott R. Genetic relatedness between the new 1977 epidemic strains (H1N1) of influenza and human influenza strains isolated between 1947 and 1957 (H1N1). Virology. 1978;89(2):613-617.
14. Rizza SR, Tangalos EG, McClees MD, et al. Nelfinavir monotherapy increases naïve T-cell numbers in HIV-negative healthy young adults. Front Biosci. 2008 Jan 1;13:1605-1609.
15. Vincent AL, Lager KM, Ma W, et al. Evaluation of hemagglutinin subtype 1 swine influenza viruses from the United States. Vet Microbiol. 2006;118(3-4):212-222.
16. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009 [published correction appears in N Engl J Med. 2009;361(1):102]. N Engl J Med. 2009;360(25):2616-2625.
17. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans [published correction appears in N Engl J Med. 2009;361(1):102]. N Engl J Med. 2009;360(25):2605-2615.
18. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
19. Kaiser J. A one-size-fits-all flu vaccine [published corrections appear in Science. 2006;312(5779):1472 and 2006;312(5776):999]? Science. 2006;312(5772):380-382. www.sciencemag.org/cgi/reprint/312/5772/380.pdf. Accessed November 30, 2009.
20. Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459(7250):1122-1125.
21. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005.
22. Boni MF. Vaccination and antigenic drift in influenza. Vaccine. 2008; 26(suppl 3):C8-C14.
23. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931-939.
24. Noble GR, Kaye HS, Kendal AP, Dowdle WR. Age-related heterologous antibody responses to influenza virus vaccination. J Infect Dis. 1977;136(suppl):S686-S692.
25. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol. 2009;45(3):174-178.
26. Rogers GN, Paulson JC. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127(2):361-373.
27. Ito T, Couceiro JN, Kelm S, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol. 1998;72(9):7367-7373.
28. Hinshaw VS, Olsen CW, Dybdahl-Sissoko N, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol. 1994;68(6):3667-3673.
29. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol. 1993;74(pt 11):2347-2355.
30. Noble RL, Lillington GA, Kempson RL. Fatal diffuse influenzal pneumonia: premortem diagnosis by lung biopsy. Chest. 1973;63(4):644-646.
31. Centers for Disease Control and Prevention (CDC). Interim guidance on case definitions to be used for investigations of novel influenza A (H1N1) cases. CDC website. http://www.dphss.guam.gov/docs/swine-flu/H1N1-Guidance/ case%20def%20june%201.pdf. Accessed November 10, 2009.
32. Nicas M, Jones RM. Relative contributions of four exposure pathways to influenza infection risk. Risk Anal. 2009;29(9):1292-1303.
33. Fabian P, McDevitt JJ, DeHaan WH, et al. Influenza virus in human exhaled breath: an observational study. PLoS ONE. 2008;3(7):e2691.
34. Maines TR, Jayaraman A, Belser JA, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009;325(5939):484-487.
35. Temte JL. Basic rules of influenza: how to combat the H1N1 influenza (swine flu) virus [editorial]. Am Fam Physician. 2009;79(11):938-939.
36. Jeannot AC, Hamoudi M, Bourayou N, et al. First cases of secondary transmission of a novel swine-origin influenza A (H1N1) virus in France [in French] [published online ahead of print July 23, 2009]. Med Mal Infect. doi:10.1016/j.medmal.2009.06.014.
37. Lye DC, Chow A, Tan A, et al. Oseltamivir therapy and viral shedding in pandemic (H1N1) 2009. In: Program and Abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 12-15, 2009 [abstract V-1269c].
38. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995;172(5):1352-1355.
39. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193(6):760-764.
40. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient [letter]. N Engl J Med. 2003;348(9):867-868.
41. World Health Organization. Preliminary information important for understanding the evolving situation: pandemic (H1N1) 2009 briefing note 4. WHO website. http://www.who.int/csr/disease/swineflu/notes/h1n1-situation-20090724/ en/index.html. Accessed November 11, 2009.
42. Centers for Disease Control and Prevention (CDC). Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58(19):521-524.
43. Komiya N, Gu Y, Kamiya H, et al. Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. Euro Surveill. 2009;14(29). pii: 19272. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19272. Accessed December 9, 2009.
44. Belgian Working Group on Influenza A(H1N1)v. Influenza A(H1N1)v virus infections in Belgium, May-June 2009. Euro Surveill. 2009;14(28). pii 19270. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19270. Accessed December 9, 2009.
45. Centers for Disease Control and Prevention(CDC). Swine-origin influenza A (H1N1) virus infections in a school - New York City, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(17):470-472.
46. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(19):536-541.
47. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(27):749-752.
48. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872-1879.
49. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-1887.
50. Rello J, Rodriguez A, Ibanez P, et al; H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain [published online ahead of print September 11, 2009]. Crit Care. 2009;13(5):R148. doi:10.1186/cc8044.
51. Centers for Disease Control and Prevention (CDC). Interim guidance for clinicians on identifying and caring for patients with swine-origin influenza A (H1N1) virus infection. CDC Web site. www.cdc.gov/h1n1flu/identifyingpatients. htm. Accessed November 11, 2009.
52. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071-1074.
53. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258-264.
54. Treanor JJ. Influenza virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:2060-2085.
55. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
56. Vaillant L, La Ruche G, Tarantola A, Barboza P; Epidemic Intelligence Team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009;14(33). pii 19309. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19309. Accessed December 9, 2009.
57. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE. 2009;4(6):e6051.
58. Centers for Disease Control and Prevention (CDC). H1N1 flu: Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. CDC Web site. www.cdc.gov/h1n1flu/recommendations.htm. Accessed November 11, 2009.
59. Centers for Disease Control and Prevention (CDC). H1N1 flu: Interim guidance on specimen collection, processing, and testing for patients with suspected novel influenza A (H1N1) virus infection. CDC Web site. www.cdc.gov/h1n1flu/specimencollection.htm. Accessed November 11, 2009.
60. Hurt AC, Baas C, Deng YM, Roberts S, Kelso A, Barr IG. Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses. Influenza Other Respi Viruses. 2009;3(4):171-176.
61. Chan KH, Lai ST, Poon LL, Guan Y, Yuen KY, Peiris JS. Analytical sensitivity of rapid influenza antigen detection tests for swine-origin influenza virus (H1N1). J Clin Virol. 2009;45(3):205-207.
62. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans [letter]. N Engl J Med. 2009; 361(7):728-729.
63. Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus-United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(30):826-829.
64. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021- 1025.
65. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(35):969-972.
66. Leung TWC, Tai ALS, Cheng PKC, Kong MSY, Lim W. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong [letter]. J Clin Virol. 2009;46:298-299.
67. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568- 1575.
68. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-1032.
69. Food and Drug Administration. Emergency use authorization (EUA) review oseltammivir phosphate for swine influenza A. FDA Web site. www.fda.gov/ downloads/Drugs/DrugSafety/ImformationbyDrugClass/UCM153547.pdf. Accessed November 11, 2009.
70. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ. 2007;176(4):463-468.
71. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148(11):1094-1102.
72. Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women [editorial]. Emerg Infect Dis. 2008;14(1):95-100.
73. Centers for Disease Control and Prevention (CDC). Novel influenza A (H1N1) virus infections in three pregnant women - United States, April-May 2009 [published correction appears in MMWR Morb Mortal Wkly Rep. 2009;58(19):541]. MMWR Morb Mortal Wkly Rep. 2009;58(18):497-500.
74. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ. 2009;181(1-2):55-58.
75. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097-1114.
76. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363-1373.
77. Loughlin JE, Alfredson TD, Ajene AN, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin Ther. 2002;24(11):1786-1799.
78. Centers for Disease Control and Prevention (CDC). Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58(39):1100-1101.
79. Greenberg ME, Lai MH, Hartel GF, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine - preliminary report [published online ahead of print September 10, 2009]. N Engl J Med. doi:10.1056/NEJMoa0907413. http://content.nejm.org/cgi/reprint/NEJMoa0907413.pdf ?resourcetype-HWCIT. Accessed November 12, 2009.
80. Fauci AS. Statement by Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, NIH, regarding early results from clinical trails of 2009 H1N1 influenza vaccines in healthy adults. US Dept Health and Human Services Web site. www.hhs.gov/news/press/2009pres/09/20090911a.html. Accessed November 12, 2009.
81. Price LC. Should I have an H1N1 flu vaccination after Guillain-Barré syndrome? BMJ. 2009;339:b3577.
82. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979;110(2):105-123.
83. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169(3):382-388.
84. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with Campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE. 2007;2(4):e344.
85. Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep. 2009;58(RR10):1-8.
86. Maurer J, Harris KM, Parker A, Lurie N. Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine. 2009;27(42):5732-5734.
87. Chor JS, Ngai KL, Goggins WB, et al. Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys. BMJ. 2009;339:b3391.
88. Centers for Disease Control and Prevention (CDC). Interim guidance for infection control for care of patients with confirmed or suspected novel influenza A (H1N1) virus infection in a healthcare setting. CDC Web site. http://www.cdc.gov/h1n1flu/guidelines-infection-control.htm. Accessed on September 13, 2009.
89. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine. 2005;23:2251-2255.
90. Poland GA. Health care workers and influenza vaccine: first do no harm, then do the right thing. J Am Pharm Assoc (2003). 2004;44(5):637-638.
91. Gomez J, Munayco C, Arrasco J, et al. Pandemic influenza in a southern hemisphere setting: the experience in Peru from May to September, 2009. Euro Surveill. 2009 Oct 22;14(42): pii 19371. http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=19371. Accessed December 9, 2009.
92. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pademics. Emerg Infect Dis. 2006;12(1):15-22.
93. Fraser C, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009;324(5934):1557- 1561.
94. Boëlle PY, Bernillon P, Desenclos JC. A preliminary estimation of the reproduction ratio for new influenza A(H1N1) from the outbreak in Mexico, March-April 2009. Euro Surveill. 2009;14(19). pii 19205. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19205. Accessed December 9, 2009.
95. Nishiura H, Wilson N, Baker MG. Estimating the reproduction number of the novel influenza A virus (H1N1) in a Southern Hemisphere setting: preliminary estimate in New Zealand [letter]. N Z Med J. 2009;122(1299):73-77.
96. Anderson RM, May RM, Anderson B. Infectious Diseases of Humans: Dynamics and Control. New York, NY: Oxford University Press; 1991:viii-757.
97. Diekmann O, Heesterbeek JAP. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation. New York, NY: John Wiley and Sons, Ltd; 2000:xi-301.
98. Sertsou G, Wilson N, Baker M, Nelson P, Roberts MG. Key transmission parameters of an institutional outbreak during the 1918 influenza pandemic estimated by mathematical modelling. Theor Biol Med Model. 2006 Nov 30;3:38.
99. Barry JM; Massachusetts Institute of Technology Engineering Systems Division. White paper on novel H1N1 - prepared for the MIT Center for Engineering Systems Fundamentals. Working paper series. Revised July 27, 2009. http://esd.mit.edu/WPS/2009/esd-wp-2009-07-072709.pdf. Accessed November 13, 2009.
100. Barry JM, Viboud C, Simonsen L. Cross-protection between successive waves of the 1918-1919 influenza pandemic: epidemiological evidence from US Army Camps and from Britain. J Infect Dis. 2008;198(10):1427-1434.
101. Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog. 2007;3(10):1414-1421.
102. Steel J, Lowen AC, Mubareka S, Palese P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog. 2009;5(1):e1000252.
103. Zamarin D, Ortigoza MB, Palese P. Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol. 2006;80(16):7976- 7983.
104. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(32):893-896.